Market Overview

This Morning's Technical Outlook on Medical Research Stocks -- Agilent Technologies, BioTelemetry, Accelerate Diagnostics, and Biocept


NEW YORK, March 16, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community.  Today we are offering reports on A, BEAT, AXDX, and BIOC which can be accessed for free by signing up to Ahead of today's trading session, covers the Medical Laboratories and Research space, which focuses on performing various tests on patients that give them information on these patients' health. Four stocks have been lined up for evaluation this morning, and they are: Agilent Technologies Inc. (NYSE: A), BioTelemetry Inc. (NASDAQ: BEAT), Accelerate Diagnostics Inc. (NASDAQ: AXDX), and Biocept Inc. (NASDAQ: BIOC). All you have to do is sign up today for this free limited time offer by clicking the link below.

Agilent Technologies

Santa Clara, California headquartered Agilent Technologies Inc.'s shares gained slightly by 0.37%, closing Thursday's trading session at $70.18. The stock recorded a trading volume of 2.49 million shares, which was above its three months average volume of 2.30 million shares. The Company's shares have advanced 2.69% in the last month, 4.65% over the previous three months, and 29.72% over the past year. The stock is trading 6.86% above its 200-day moving average. Additionally, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 52.07. 

On March 12th, 2018, Agilent Technologies announced that it has received two 2018 Scientists' Choice Awards: Best New Separation Product for the Agilent 1260 Infinity II Prime LC system, and Best New Spectroscopy Product for the Agilent Ultivo Triple Quadrupole LC/MS system. SelectScience announced the winners of the 2018 Scientists' Choice Awards during a special ceremony held on February 28th, 2018 at the international conference Pittcon 2018 in Orlando Florida. Get the full research report on A for free by clicking below at:


On Thursday, shares in Malvern, Pennsylvania headquartered BioTelemetry Inc. recorded a trading volume of 321,434 shares. The stock declined slightly by 0.59%, ending the day at $33.70. The Company's shares have advanced 2.28% in the past month, 19.08% in the previous three months, and 24.35% over the past year. The stock is trading above its 50-day and 200-day moving averages by 2.03% and 5.76%, respectively. Furthermore, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 50.84. 

On February 22nd, 2018, BioTelemetry reported its results for Q4 ended December 31st, 2017. The Company recognized the highest quarterly revenue in its history of $91.7 million and realized a record quarterly adjusted EBITDA of $22.9 million. Gross profit for Q4 2017 was $54.4 million, and GAAP net loss attributable to the Company was $(15.6) million.

On February 23rd, 2018, research firm Dougherty & Company reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $40 a share to $41 a share. BEAT's complimentary research coverage is a few simple steps away at:

Accelerate Diagnostics

Tucson, Arizona headquartered Accelerate Diagnostics Inc.'s stock finished the day 2.70% lower at $25.20 with a total trading volume of 235,327 shares. The Company's shares have advanced 10.04% in the last month and 13.77% over the past year. The stock is trading above its 200-day moving average by 0.16%. Additionally, shares of Accelerate Diagnostics, which provides solutions for the diagnosis of serious infections in the US, have an RSI of 45.69. Register for your free research report on AXDX at:


Shares in San Diego, California headquartered Biocept Inc. ended yesterday's session 4.17% lower at $0.34. The stock recorded a trading volume of 8.41 million shares, which was above its three months average volume of 2.18 million shares. The Company's shares have advanced 15.58% in the last month. The stock is trading 21.31% below its 50-day moving average. Moreover, shares of Biocept, which develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample, have an RSI of 45.15. 

On March 12th, 2018, Biocept announced that it will release its financial results for the three and twelve months ended December 31st, 2017, after market closes on March 28th, 2018. The Company will host a conference call for the investment community at 4:30 p.m. ET that same day to discuss its results and answer questions. Wall St. Equities' downloadable research report on BIOC available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at